Cara Therapeutics plans to discontinue its clinical program for notalgia paresthetica, resulting in a reduction in workforce and approximately $2.6 million in charges.
AI Assistant
TVARDI THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.